TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16456674

Group type: EXPERIMENTAL
Intervention: 6% CHO solution
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 6 g EAA mixture
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: CHO + EAA supplement
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 32
Study: 14743972

Group type: EXPERIMENTAL
Intervention: Single dose theophylline (USRT)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Multiple doses theophylline (USRT)
Number of subjects: 8
Study: 11185672

Group type: EXPERIMENTAL
Intervention: Fixed-combination metformin/glyburide tablets (500 mg/2.5 mg and 500 mg/5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin/glyburide (500 mg/5 mg) tablet with food
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin/glyburide (500 mg/5 mg) tablet in fasted condition
Number of subjects: 0
Study: 9382122

Group type: EXPERIMENTAL
Intervention: Ibandronate 0.5 mg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Ibandronate 1 mg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Ibandronate 2 mg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Ibandronate (all doses)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Ibandronate (2 mg)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 1550171

Group type: EXPERIMENTAL
Intervention: Transdermal continuous 17 beta‐estradiol, 0.05 mg/day, with transdermal cyclic norethindrone acetate, 0.25 mg/day
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Oral continuous conjugated equine estrogens, 0.625 mg/day, with oral cyclic dl‐norgestrel, 0.15 mg/day
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (29 untreated subjects)
Number of subjects: 61
Study: 3560612

Group type: EXPERIMENTAL
Intervention: 30 mg nifedipine (corinfar)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 80 mg propranolol (anaprilin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 60 mg propranolol and 20 mg nifedipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 80 mg propranolol (anaprilin) and 30 mg nifedipine (corinfar)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31056685

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium lactis, 109 colony‐forming units per capsule) for 8 weeks
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 28443834

Group type: COMPARATOR
Intervention: None (G2)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine (30s) (G3)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Prolonged primer application (1 min) (G4)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Roughening with a diamond bur (G5)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 10.5% NaOCl (1 min) (G6)
Number of subjects: 36
Study: 25716646

Group type: EXPERIMENTAL
Intervention: Exposure to McDonald's Happy Meal® adverts depicting healthy meal bundles (fish fingers, fruit bag, mineral water)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control condition (exposure to ten toy adverts)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Exposure to food adverts
Number of subjects: 59
Study: 24370154

Group type: EXPERIMENTAL
Intervention: 240‐mg/mL contrast material at 80 kVp
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 300‐mg/mL contrast material at 80 kVp
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 370‐mg/mL contrast material at 120 kVp
Number of subjects: 109
Study: 22943970

Group type: EXPERIMENTAL
Intervention: DA-1229 10 mg after a high-fat meal
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: DA-1229 (various doses: 1.25, 2.5, 5, 10, 20, 40, 60 mg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: DA-1229 (various doses)
Number of subjects: 72
Study: 19740126

Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg/day
Number of subjects: 584

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 584
Study: 17332965

Group type: EXPERIMENTAL
Intervention: Ultrasonic scalpel
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High light intensity
Number of subjects: 50

Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low light intensity
Number of subjects: 50
Study: 15333074

Group type: EXPERIMENTAL
Intervention: Pacing from the pulmonary vein (PV) at cycle lengths of 700 ms
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pacing from the pulmonary vein (PV) at cycle lengths of 300 ms
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group pacing from the distal coronary sinus at 700 ms
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group pacing from the distal coronary sinus at 300 ms
Number of subjects: 20
Study: 11605809

Group type: EXPERIMENTAL
Intervention: Ceftibuten 200 mg twice daily
Number of subjects: 45

Group type: COMPARATOR
Intervention: Cefixime 200 mg twice daily
Number of subjects: 45
Study: 9467759

Group type: EXPERIMENTAL
Intervention: High homophobia individuals
Number of subjects: 3

Group type: COMPARATOR
Intervention: Medium homophobia individuals
Number of subjects: 3

Group type: COMPARATOR
Intervention: Low homophobia individuals
Number of subjects: 3
Study: 18800460

Group type: EXPERIMENTAL
Intervention: losartan 50 mg
Number of subjects: 135

Group type: COMPARATOR
Intervention: lisinopril 20 mg
Number of subjects: 135

Group type: COMPARATOR
Intervention: hydrochlorothiazide 25 mg
Number of subjects: 135
Study: 2653175

Group type: EXPERIMENTAL
Intervention: 1 mg naloxone hydrochloride
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 10 mg naloxone hydrochloride
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 30 mg naloxone hydrochloride (single blind)
Number of subjects: 54
Study: 794422

Group type: EXPERIMENTAL
Intervention: Inactivated Mycoplasma pneumoniae vaccine, 1-ml dose administered by jet-injection device.
Number of subjects: 7861

Group type: COMPARATOR
Intervention: Phosphate-buffered saline (placebo) administered similarly to control subjects.
Number of subjects: 7861

Group type: EXPERIMENTAL
Intervention: Inactivated Mycoplasma pneumoniae vaccine
Number of subjects: 7861
Study: 28940403

Group type: EXPERIMENTAL
Intervention: Percutaneous Endoscopic Gastrostomy (PEG)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Radiologically Inserted Gastrostomy (RIG)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 214
Study: 26252534

Group type: EXPERIMENTAL
Intervention: ASM-024 50 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ASM-024 200 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 23589742

Group type: EXPERIMENTAL
Intervention: Home death preference
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Living with at least one relative
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Symptom burden two days before death
Number of subjects: 310

Group type: COMPARATOR
Intervention: Quality of care on standard hospital wards
Number of subjects: 310
Study: 21727232

Group type: EXPERIMENTAL
Intervention: Escitalopram (12-week treatment)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo (12-week treatment)
Number of subjects: 160
Study: 19853689

Group type: EXPERIMENTAL
Intervention: M118
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 0
Study: 16732081

Group type: EXPERIMENTAL
Intervention: Intravenous fructose infusion (0.5 g . kg(‐1) . h(‐1) for 4 h, starting 3 h before induction of anesthesia)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravenous fructose infusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study: 14715339

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 10003

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 10003
Study: 11374137

Group type: EXPERIMENTAL
Intervention: Video Assisted Thoracoscopy (VATS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Insertion of Chest Tube (ICT)
Number of subjects: 40
Study: 9228213

Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg per day
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 8015690

Group type: EXPERIMENTAL
Intervention: Heparan sulfate
Number of subjects: 80

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 80
Study: 6418110

Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lithium carbonate (after placebo)
Number of subjects: 15
Study: 31854292

Group type: EXPERIMENTAL
Intervention: Usual care plus the RESPECT intervention (three sessions of 1 hour)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Usual care only (control arm)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Usual care plus the RESPECT intervention
Number of subjects: 72
Study: 29122190

Group type: EXPERIMENTAL
Intervention: Feedback screens with flight path of all target aircraft and triangular graphs of both RCJ scores and human performance (Group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Feedback screens with flight path of all target aircraft only (Group B)
Number of subjects: 0
Study: 27697878

Group type: EXPERIMENTAL
Intervention: YP Face IT online psychosocial intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study: 24747297

Group type: EXPERIMENTAL
Intervention: 200 ppb NO2
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 600 ppb NO2
Number of subjects: 19

Group type: COMPARATOR
Intervention: Clean air
Number of subjects: 19
Study: 22089105

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) monotherapy for 9 weeks
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Atenolol monotherapy for 9 weeks
Number of subjects: 569

Group type: COMPARATOR
Intervention: Add-on therapy with HCTZ after atenolol
Number of subjects: 569

Group type: COMPARATOR
Intervention: Add-on therapy with atenolol after HCTZ
Number of subjects: 569
Study: 19770623

Group type: COMPARATOR
Intervention: Foreskin surface area in the lowest quartile (≤26.3 cm²)
Number of subjects: 965

Group type: EXPERIMENTAL
Intervention: Foreskin surface area in the second quartile (26.4-35.0 cm²)
Number of subjects: 965

Group type: EXPERIMENTAL
Intervention: Foreskin surface area in the third quartile (35.2-45.5 cm²)
Number of subjects: 965

Group type: EXPERIMENTAL
Intervention: Foreskin surface area in the highest quartile (>45.6 cm²)
Number of subjects: 965

Group type: COMPARATOR
Intervention: Comparison of highest quartile (>45.6 cm²) to lowest quartile (≤26.3 cm²)
Number of subjects: 965
Study: 17233848

Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 195

Group type: COMPARATOR
Intervention: Deferoxamine
Number of subjects: 195
Study: 16199188

Group type: EXPERIMENTAL
Intervention: TKA731 (150 mg daily)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 15206646

Group type: EXPERIMENTAL
Intervention: Betaxolol 0.50% twice daily
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily
Number of subjects: 31

Group type: COMPARATOR
Intervention: Comparison of latanoprost to betaxolol
Number of subjects: 31
Study: 11775949

Group type: EXPERIMENTAL
Intervention: Mifepristone 300 mg plus misoprostol 1,200 micrograms over 6 days
Number of subjects: 1621

Group type: COMPARATOR
Intervention: Mifepristone 150 mg plus misoprostol 600 micrograms over 3 days
Number of subjects: 1621
Study: 8721493

Group type: EXPERIMENTAL
Intervention: Histamine injections (0.1 micrograms each)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline injections (control)
Number of subjects: 40
Study: 1807007

Group type: EXPERIMENTAL
Intervention: Sulindac (100 mg x 3 per day)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (25 mg x 3 per day)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Nifedipine (20 mg x 2 per day in slow releasing form)
Number of subjects: 6
Study: 6338381

Group type: EXPERIMENTAL
Intervention: 10-drug regimen (modified LSA2-L2)
Number of subjects: 234

Group type: COMPARATOR
Intervention: 4-drug regimen (COMP)
Number of subjects: 234
Study: 31647384

Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 190

Group type: COMPARATOR
Intervention: Attention control group (physical activity recommendations)
Number of subjects: 190
Study: 30289287

Group type: EXPERIMENTAL
Intervention: NI-071 (infliximab biosimilar)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Infliximab reference product (RP)
Number of subjects: 0
Study: 26818533

Group type: EXPERIMENTAL
Intervention: Loving-kindness and compassion meditation (LKM/CM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mindfulness continuation training (control group)
Number of subjects: 0
Study: 25795948

Group type: EXPERIMENTAL
Intervention: Cowpea protein isolate (25 g/day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Casein (25 g/day)
Number of subjects: 38
Study: 23348922

Group type: EXPERIMENTAL
Intervention: Novel anticoagulants (specific types not mentioned) in PROBE trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel anticoagulants (specific types not mentioned) in double-blind trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin (VKA) control in PROBE trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin (VKA) control in double-blind trials
Number of subjects: 0
Study: 20697787

Group type: EXPERIMENTAL
Intervention: Language concordant group
Number of subjects: 191

Group type: COMPARATOR
Intervention: Language discordant group
Number of subjects: 191
Study: 19711135

Group type: EXPERIMENTAL
Intervention: Perceived susceptibility to chronic kidney disease (CKD) assessed via questionnaire
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Blood pressure management adherence assessed via Hill-Bone blood pressure adherence scale
Number of subjects: 195
Study: 17039397

Group type: EXPERIMENTAL
Intervention: CASPAR Youth Services Student Assistance Program (psycho-educational small-group component)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 15297828

Group type: EXPERIMENTAL
Intervention: 6-mm grafts
Number of subjects: 70

Group type: COMPARATOR
Intervention: 6- to 8-mm grafts
Number of subjects: 70
Study: 11061861

Group type: EXPERIMENTAL
Intervention: (51)Cr-labeled RBCs before surgery
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: (51)Cr-labeled RBCs after surgery
Number of subjects: 5
Study: 9487834

Group type: EXPERIMENTAL
Intervention: Essential oil dentifrice containing 1.3% pyrophosphate ion (PPi)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control dentifrice (Crest Regular)
Number of subjects: 150
Study: 8257550

Group type: EXPERIMENTAL
Intervention: Mepivacaine 1%
Number of subjects: 100

Group type: COMPARATOR
Intervention: Prilocaine 1%
Number of subjects: 100
Study: 3929873

Group type: EXPERIMENTAL
Intervention: verapamil (n = 6)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: isosorbide dinitrate (n = 10)
Number of subjects: 21

Group type: COMPARATOR
Intervention: labetalol (n = 5)
Number of subjects: 21
Study: 31615381

Group type: EXPERIMENTAL
Intervention: Volume-controlled ventilation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation
Number of subjects: 12
Study: 30018370

Group type: EXPERIMENTAL
Intervention: Cricket-containing breakfast foods for 14 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control breakfast foods for 14 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cricket consumption
Number of subjects: 20
Study: 26655860

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Placebo (stretching) exercise
Number of subjects: 35

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 35
Study: 25473213

Group type: EXPERIMENTAL
Intervention: Polydeoxyribonucleotide (PDRN) administered intramuscularly (1 ampule, 3 mL, 5.625 mg, for 5 days) for 2 weeks and perilesionally (1 ampule, 3 mL, 5.625 mg, twice a week) for 4 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 23
Study: 22187387

Group type: EXPERIMENTAL
Intervention: 18° camber
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 20° camber
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 15° camber
Number of subjects: 14

Group type: COMPARATOR
Intervention: 24° camber
Number of subjects: 14
Study: 20660401

Group type: EXPERIMENTAL
Intervention: Rehabilitation plus early ACL reconstruction
Number of subjects: 121

Group type: COMPARATOR
Intervention: Rehabilitation plus optional delayed ACL reconstruction
Number of subjects: 121
Study: 18616658

Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.i.d.
Number of subjects: 2667

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2667
Study: 16038823

Group type: EXPERIMENTAL
Intervention: Surgical Pain Scales (SPS) measuring pain during normal activities
Number of subjects: 2164

Group type: EXPERIMENTAL
Intervention: Surgical Pain Scales (SPS) measuring pain while at rest, pain during normal activities, pain during work or exercise, and pain unpleasantness
Number of subjects: 2164

Group type: EXPERIMENTAL
Intervention: Surgical Pain Scales (SPS) compared with SF-36 health status instrument
Number of subjects: 2164
Study: 11379344

Group type: EXPERIMENTAL
Intervention: Bionormalizer (18 g/day for 2 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (flavored sugar)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study: 9589226

Group type: EXPERIMENTAL
Intervention: Hypocaloric formula diet (1,100 +/- 60 kcal/day; 33% protein, 38% carbohydrate, 29% fat)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Hypocaloric formula diet
Number of subjects: 18
Study: 8026229

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil-interferon-alpha 2b
Number of subjects: 57

Group type: COMPARATOR
Intervention: 5-fluorouracil alone
Number of subjects: 57
Study: 2917924

Group type: EXPERIMENTAL
Intervention: 0.4 ppm ozone exposure
Number of subjects: 18
Study: 1091127

Group type: EXPERIMENTAL
Intervention: Clofibrate (2 gm. daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clofibrate
Number of subjects: 40
Study: 31477185

Group type: EXPERIMENTAL
Intervention: Gravid oviposition sticky (GOS) trap and dengue non-structural 1 (NS1) antigen test
Number of subjects: 8
Study: 28600953

Group type: EXPERIMENTAL
Intervention: Manualized cognitive therapy (mCT)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Cognitive-behavioral treatment-as-usual (CBTAU)
Number of subjects: 162
Study: 26082625

Group type: EXPERIMENTAL
Intervention: QVA149 110/50 μg once daily
Number of subjects: 744

Group type: COMPARATOR
Intervention: SFC 50/500 μg twice daily
Number of subjects: 744
Study: 23365106

Group type: EXPERIMENTAL
Intervention: WL+FAEE (4 g/d Omacor)
Number of subjects: 25

Group type: COMPARATOR
Intervention: WL (25% energy deficit weight loss diet)
Number of subjects: 25
Study: 21274983

Group type: EXPERIMENTAL
Intervention: Erythromycin (1000 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (NaCl solution)
Number of subjects: 12
Study: 18988916

Group type: EXPERIMENTAL
Intervention: Robot virtual reality (VR) system
Number of subjects: 18

Group type: COMPARATOR
Intervention: Robot alone
Number of subjects: 18
Study: 17053350

Group type: EXPERIMENTAL
Intervention: Tenofovir DF
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Abacavir
Number of subjects: 105
Study: 12721716

Group type: EXPERIMENTAL
Intervention: Tissue glue
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 0
Study: 10947692

Group type: EXPERIMENTAL
Intervention: Propofol 3 mg.kg‐1 and succinylcholine 1 mg.kg‐1 (n = 40)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propofol 3 mg.kg‐1 and alfentanil 10 microg.kg‐1 (n = 40)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sevoflurane 8% in 60% nitrous oxide in oxygen for 3 min (n = 40)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Propofol 3 mg.kg‐1 and succinylcholine 1 mg.kg‐1 or Sevoflurane 8%
Number of subjects: 120
Study: 8997677

Group type: EXPERIMENTAL
Intervention: CC + GTR
Number of subjects: 80

Group type: COMPARATOR
Intervention: GTR
Number of subjects: 80

Group type: COMPARATOR
Intervention: CC
Number of subjects: 80

Group type: COMPARATOR
Intervention: GFS
Number of subjects: 80
Study: 1635933

Group type: EXPERIMENTAL
Intervention: Divitabs (sustained release preparation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal carbamazepine preparation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Divitabs
Number of subjects: 20
Study: 6234240

Group type: EXPERIMENTAL
Intervention: Bacterial extract
Number of subjects: 20
Study: 29566095

Group type: EXPERIMENTAL
Intervention: Cavendish banana (CAV)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mini-yellow banana (MIY)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 6% sugar beverage (SUG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Water only (WAT)
Number of subjects: 20
Study: 26879069

Group type: EXPERIMENTAL
Intervention: High-dose rosuvastatin (20 mg/day, n = 18)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Low-dose rosuvastatin (2.5 mg/day, n = 19)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Comparison of high-dose vs low-dose rosuvastatin
Number of subjects: 37
Study: 25915488

Group type: EXPERIMENTAL
Intervention: Hypocaloric bedrest
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normocaloric ambulatory
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normocaloric bedrest
Number of subjects: 9
Study: 23065047

Group type: EXPERIMENTAL
Intervention: Topical antiglaucoma medication
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Patient knowledge of glaucoma
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Forgetfulness
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Herbal medicine
Number of subjects: 581
Study: 21119128

Group type: EXPERIMENTAL
Intervention: AMSA nerve block
Number of subjects: 28

Group type: COMPARATOR
Intervention: IONB
Number of subjects: 28
Study: 18231908

Group type: EXPERIMENTAL
Intervention: Rituximab plus cyclophosphamide, vincristine and prednisolone (R-CVP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclophosphamide, vincristine and prednisolone (CVP)
Number of subjects: 0